Alto Ingredients Future Growth
Future criteria checks 0/6
Alto Ingredients's earnings are forecast to decline at 41.8% per annum while its annual revenue is expected to grow at 0.4% per year. EPS is expected to decline by 44.4% per annum.
Key information
-41.8%
Earnings growth rate
-44.36%
EPS growth rate
| Chemicals earnings growth | 21.7% |
| Revenue growth rate | 0.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 06 Aug 2026 |
Recent future growth updates
Recent updates
Seeking Alpha • Sep 16
Alto Ingredients: The Market Is Overestimating An Essential Item, And Why I Am Bearish
Summary Alto Ingredients trades at $3.90, reflecting a sharp decline due to rising corn prices and near-zero crush margins. Co-products, reported as essential ingredients, generated $53.9M in Q2 FY2026, covering over half of corn costs and stabilizing earnings. ALTO’s earnings resilience stems from essential ingredients revenue, which offsets negative ethanol margins when corn prices spike. Recent operational moves include acquiring Kodiak Carbonic and idling the Magic Valley plant to optimize financial performance. Read the full article on Seeking AlphaAnalysis Article • Aug 08
Alto Ingredients, Inc. Just Beat EPS By 76%: Here's What Analysts Think Will Happen Next
A week ago, Alto Ingredients, Inc. ( NASDAQ:ALTO ) came out with a strong set of quarterly numbers that could...Analysis Article • Jun 18
Alto Ingredients (ALTO) Stock Could Be 44.3% Undervalued After $8.9 Million 45Z Credit Sale
Alto Ingredients (ALTO) has drawn fresh attention after monetizing its 2025 Section 45Z Clean Fuel Production Tax Credits, securing about $8.9 million in cash that ties directly to its low-carbon ethanol operations. See our latest analysis for Alto Ingredients. That cash injection from Section 45Z tax credits lands at a time when Alto Ingredients’ share price has risen 88.53% year to date, with a 30 day share price return of 6.25% and a one year total shareholder return of 332.33%. These...
Narrative Update • Jun 18
ALTO: Stock Outlook Will Center On Future Clean Fuel Tax Credits
The analyst price target for Alto Ingredients has been revised from about $5.50 to roughly $10.00. Analysts attribute this change to updated assumptions on discount rates, profitability, and future P/E expectations.
Narrative Update • Jun 04
ALTO: Funded MASH Path And Liver Programs Are Expected To Drive Upside
Analysts have lifted the fair value estimate for Alto Ingredients to $9.00 from $6.75, reflecting updated assumptions around revenue growth, margins, and a lower projected P/E multiple informed by recent Street research on comparable clinical and funding setups. Analyst Commentary Recent Street research on peer companies in adjacent clinical and funding situations highlights how valuation work is being reshaped by dilution, funding visibility, and evolving program focus.
Narrative Update • May 15
ALTO: Future Returns Will Hinge On MASH Trials And Alcohol Liver Data
Alto Ingredients' analyst price target has been revised higher to $8.00 from $4.50, with analysts citing updated assumptions about the discount rate, revenue growth, profit margin, and future P/E to reflect recent research on the company's pipeline and market opportunities. Analyst Commentary While the revised US$8.00 price target reflects updated assumptions about Alto Ingredients' potential, some of the broader Street research on comparable stocks highlights why not all analysts are leaning in aggressively on valuation.Narrative Update • Apr 23
ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential
Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs. Analyst Commentary Bullish Takeaways Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease.Narrative Update • Apr 09
ALTO: Future Returns Will Depend On MASH Trials And Alcohol Liver Data
Analysts have raised Alto Ingredients' price target to $25 from $12, citing pemvidutide's potential in MASH and alcohol-related liver and use disorders as key factors behind the revision. Analyst Commentary Recent Street research on Alto Ingredients highlights a mixed backdrop, with optimistic views on pemvidutide and the MASH program set against more cautious assessments of risk and valuation.Narrative Update • Mar 26
ALTO: Future Returns Will Hinge On MASH Trials And Funding Discipline
Analysts have raised their average price target for Alto Ingredients to $25 from $12, citing a sharpened focus on the planned MASH pivotal program and added potential value from pemvidutide in alcohol use disorder and alcohol liver disease, along with a solid cash runway and upcoming clinical catalysts. Analyst Commentary Recent Street research on Altimmune reflects a mix of optimism around the clinical pipeline and caution around execution risks and valuation.Narrative Update • Mar 11
ALTO: Future Returns Will Depend On Execution And Funding Discipline
Analysts have raised their price target on Alto Ingredients to $4.50 from $3.00, citing updated assumptions around fair value, discount rate, expected revenue growth, profit margins, and future P/E that they say are more in line with recent Street research on comparable companies. Analyst Commentary While the higher price target reflects updated valuation work, some bearish analysts in the broader small cap space are still emphasizing execution and funding risks that can weigh on sentiment for companies like Alto Ingredients.Narrative Update • Feb 25
ALTO: Future Upside Will Depend On Delivering Consistent Margin Execution
Analysts have adjusted their price target on Alto Ingredients to $3.00, with the neutral fair value and updated assumptions on discount rate, revenue growth, profit margin, and future P/E reflecting a refined view of the company’s risk and earnings profile following recent supportive research coverage. Analyst Commentary Recent research on Alto Ingredients has focused on reassessing the balance between potential upside and the risks tied to execution, earnings quality, and market conditions.Narrative Update • Feb 11
ALTO: Fair Outlook Will Rely On Sustaining Margins And Execution
Analysts have raised their price target for Alto Ingredients to US$3.00, reflecting updated views that include modestly higher revenue growth, slightly stronger profit margins, a lower discount rate, and a revised future P/E assumption, supported in part by recent bullish Street research. Analyst Commentary While the updated US$3.00 price target points to a more constructive stance overall, some bearish analysts remain cautious and continue to flag risk around how Alto Ingredients can justify this valuation through execution and earnings delivery.Narrative Update • Jan 27
ALTO: Upcoming Liver Meeting Data Will Support Repriced Risk Reward Profile
Analysts recently trimmed their 12 month price target on Alto Ingredients by US$1 to US$14, citing refreshed assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts trimming price targets on comparable small cap names to around US$14, even when maintaining constructive ratings, suggest a tighter margin for error around assumptions such as discount rates, revenue growth, profit margins, and future P/E multiples.Narrative Update • Jan 12
ALTO: Upcoming Late-Stage Liver Data Will Support Repriced Risk Reward Profile
Narrative Update: Alto Ingredients Analyst Price Target Shift Analysts have trimmed their price target on Alto Ingredients by $1 to $14, citing updated risk and growth assumptions after the timing and outlook of recent clinical data were refined. Analyst Commentary Recent Street research reflects a more cautious tone, with bearish analysts trimming price targets and rechecking their assumptions on risk and potential upside.Narrative Update • Dec 26
ALTO: Upcoming Late-Stage Data Will Shape Risk Profile Amid Measured Outlook
Analysts have modestly lowered their price target on Alto Ingredients, trimming fair value by $1 to $14 as they factor in slightly softer long term assumptions, while remaining encouraged by upcoming late stage data presentations. Analyst Commentary Bearish analysts have pointed to the recent price target reduction to $14 as evidence that expectations for Alto Ingredients' long term growth and profitability are being tempered, even as upcoming late stage data remains a potential catalyst.Analysis Article • Dec 22
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Shares Leap 41% Yet They're Still Not Telling The Full Story
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 41% gain in the last month...Narrative Update • Dec 12
ALTO: Lower Discount Rate Will Support Improved Risk Profile Ahead
Analysts have raised their price target on Alto Ingredients by about $0.50, citing a lower perceived risk profile driven by a reduced discount rate, stronger expected revenue growth, and a modest improvement in projected profit margins and future valuation multiples. Analyst Commentary Bearish analysts remain cautious on Alto Ingredients despite the recent upward revision to the price target, emphasizing that the new target still embeds a meaningful discount to peers on key growth and profitability metrics.Analysis Article • Nov 07
Alto Ingredients, Inc. (NASDAQ:ALTO) Shares Fly 28% But Investors Aren't Buying For Growth
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 28% gain in the last month...Analysis Article • Jul 04
Alto Ingredients, Inc. (NASDAQ:ALTO) Held Back By Insufficient Growth Even After Shares Climb 31%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 31% gain in the last month...
New Narrative • May 04
CO2 Plant Integration Will Boost Production And Exports
Acquisition and integration of the CO2 processing plant are expected to improve financials through cost synergies, increased capacity, and enhanced revenue streams.Analysis Article • Apr 22
Health Check: How Prudently Does Alto Ingredients (NASDAQ:ALTO) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Nov 12
Alto Ingredients (NASDAQ:ALTO) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jul 17
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Analysis Article • Jun 28
Would Alto Ingredients (NASDAQ:ALTO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jan 15
Here's Why Alto Ingredients (NASDAQ:ALTO) Can Afford Some Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • Dec 20
Alto Ingredients, Inc. (NASDAQ:ALTO) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Those holding Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares would be relieved that the share price has rebounded 25% in...Analysis Article • Sep 15
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Apr 10
We Think Alto Ingredients (NASDAQ:ALTO) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 951 | 26 | 41 | 60 | 2 |
| 12/31/2026 | 954 | 29 | 42 | 67 | 2 |
| 6/30/2026 | 943 | 51 | 50 | 65 | N/A |
| 3/31/2026 | 916 | 28 | 31 | 36 | N/A |
| 12/31/2025 | 918 | 12 | 9 | 13 | N/A |
| 9/30/2025 | 922 | -51 | -10 | -6 | N/A |
| 6/30/2025 | 933 | -68 | -13 | -10 | N/A |
| 3/31/2025 | 951 | -60 | -30 | -23 | N/A |
| 12/31/2024 | 965 | -60 | -15 | -4 | N/A |
| 9/30/2024 | 1,003 | -37 | 3 | 18 | N/A |
| 6/30/2024 | 1,069 | -39 | 2 | 23 | N/A |
| 3/31/2024 | 1,150 | -28 | 22 | 47 | N/A |
| 12/31/2023 | 1,223 | -29 | -8 | 22 | N/A |
| 9/30/2023 | 1,278 | -43 | -23 | 14 | N/A |
| 6/30/2023 | 1,297 | -68 | -73 | -28 | N/A |
| 3/31/2023 | 1,341 | -53 | -73 | -28 | N/A |
| 12/31/2022 | 1,336 | -43 | -32 | 6 | N/A |
| 9/30/2022 | 1,393 | 26 | 19 | 48 | N/A |
| 6/30/2022 | 1,361 | 51 | 22 | 43 | N/A |
| 3/31/2022 | 1,297 | 37 | 28 | 42 | N/A |
| 12/31/2021 | 1,208 | 44 | 10 | 27 | N/A |
| 9/30/2021 | 991 | -12 | -37 | -24 | N/A |
| 6/30/2021 | 890 | 7 | 22 | 30 | N/A |
| 3/31/2021 | 804 | 13 | 31 | 40 | N/A |
| 12/31/2020 | 897 | -16 | 65 | 72 | N/A |
| 9/30/2020 | 1,086 | -37 | 74 | 80 | N/A |
| 6/30/2020 | 1,246 | -80 | 44 | 48 | N/A |
| 3/31/2020 | 1,380 | -102 | N/A | 19 | N/A |
| 12/31/2019 | 1,425 | -90 | N/A | -31 | N/A |
| 9/30/2019 | 1,402 | -81 | N/A | -52 | N/A |
| 6/30/2019 | 1,407 | -61 | N/A | -29 | N/A |
| 3/31/2019 | 1,471 | -67 | N/A | -22 | N/A |
| 12/31/2018 | 1,515 | -62 | N/A | 2 | N/A |
| 9/30/2018 | 1,576 | -43 | N/A | 28 | N/A |
| 6/30/2018 | 1,651 | -36 | N/A | 26 | N/A |
| 3/31/2018 | 1,646 | -31 | N/A | 33 | N/A |
| 12/31/2017 | 1,632 | -36 | N/A | 37 | N/A |
| 9/30/2017 | 1,679 | -10 | N/A | 57 | N/A |
| 6/30/2017 | 1,651 | -13 | N/A | 51 | N/A |
| 3/31/2017 | 1,669 | 1 | N/A | 54 | N/A |
| 12/31/2016 | 1,625 | 0 | N/A | 37 | N/A |
| 9/30/2016 | 1,560 | -14 | N/A | 6 | N/A |
| 6/30/2016 | 1,523 | -25 | N/A | -37 | N/A |
| 3/31/2016 | 1,327 | -29 | N/A | -39 | N/A |
| 12/31/2015 | 1,191 | -20 | N/A | -28 | N/A |
| 9/30/2015 | 1,071 | -7 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALTO's earnings are forecast to decline over the next 3 years (-41.8% per year).
Earnings vs Market: ALTO's earnings are forecast to decline over the next 3 years (-41.8% per year).
High Growth Earnings: ALTO's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ALTO's revenue (0.4% per year) is forecast to grow slower than the US market (13.6% per year).
High Growth Revenue: ALTO's revenue (0.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALTO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 03:51 |
| End of Day Share Price | 2026/09/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alto Ingredients, Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carter Driscoll | B. Riley Securities, Inc. |
| Hamed Khorsand | BWS Financial Inc. |
| Eric Stine | Craig-Hallum Capital Group LLC |